KRAS is the most commonly mutated gene in cancer, responsible for mutations in 17% to 25% of all cases. This gene plays a critical role in driving uncontrolled tumor cell growth, making it a primary target in cancer drug discovery. However, current treatments are limited. Only one KRAS mutation, known as G12C, has a targeted therapy, leaving many patients without effective options. To address this gap, researchers have developed ACBI3, a new molecule based on PROTACs (PRoteolysis TArgeting Chimeras). This promising innovation has been shown to eliminate 13 out of the 17 most common KRAS mutati…